<!DOCTYPE HTML>
<html lang="es">

<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>

<body>

	<div class='preloader'>
		<div class='loaded'>&nbsp;</div>
	</div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
						<nav class="navbar navbar-default">
							<div class="container-fluid">
								<!-- Brand and toggle get grouped for better mobile display -->
								<div class="navbar-header">
									<button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
									</button>
									<a class="navbar-brand" href="index.html">
										<div class="logo">
											<img src="images/vikhiLOGOsm.png" alt="" height="30">
										</div>
									</a>
								</div>

								<!-- Collect the nav links, forms, and other content for toggling -->
								<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

									<ul class="nav navbar-nav navbar-right">
										<li><a href="indice.html">ÍNDICE</a></li>

									</ul>
								</div><!-- /.navbar-collapse -->
							</div><!-- /.container-fluid -->
						</nav>
					</div>
				</div>
				<!--Fin de row -->

			</div>
			<!--Fin de container -->

		</div>
	</header>
	<!--Fin de header -->

	<section>
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="parrafo text-center wow fadeIn" data-wow-duration="1.5s">
							<video width="720" height="" controls>
								<source src="videos/jornadaVIKHI06.mp4" type="video/mp4">
							</video>
							<div class="single_right_text text-center">
								<br>
								<br>
								<br>
								<h6>6<span class="negrita">.</span> Toxicidad neurológica, cardiológica y osteomuscular</h6>

							</div>
							<div class="single_right_text text-center">
								<br>
								<br>

								<p class="text-center">Dra. Roser Velasco <span class="negrita">/</span> Servicio de Neurología, Hospital Universitario de Bellvitge</p>
								<p class="text-center">Dra. Elena García Romero <span class="negrita">/</span> Servicio de Cardiología, Hospital Universitario de Bellvitge</p>
								<p class="text-center">Dr. Francisco Javier Narváez <span class="negrita">/</span> Servicio de Reumatología, Hospital Universitario de Bellvitge</p>
							</div>


							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<p>Descarga los archivos relacionados con este video haciendo click en los siguientes enlaces:</p>
									<p><span class="gris">Download the articles on the subject by clicking on the links below:</span></p>
									<br>
									<table class="vikhi-tablalink">
										<tr>
											<td><a href=docs/roserVelasco.pdf download><img src="images/download.png" alt="" height="20px"></a></td>
											<td>
												<p><a href=docs/roserVelasco.pdf download>Neurological toxicity induced by immunotherapy</a></p>
											</td>
										</tr>
										<tr>
											<td><a href=docs/elenaGarcia.pdf download><img src="images/download.png" alt="" height="20px"></a></td>
											<td>
												<p><a href=docs/elenaGarcia.pdf download>Cardiotoxicity associated with immunotherapy</a></p>
											</td>
										</tr>
										<tr>
											<td><a href=docs/javierNarvaez.pdf download><img src="images/download.png" alt="" height="20px"></a></td>
											<td>
												<p><a href=docs/javierNarvaez.pdf download>Immunotherapy-induced rheumatic autoimmune disorders</a></p>
											</td>
										</tr>
									</table>
								</div>
							</div>


							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<img src="images/ICONOdocumento.png" alt="" height="50px">
									<br>
									<br>
									<h4>NEUROLOGICAL TOXICITY</h4>
									<br>
									<p>Dra. Roser Velasco <span class="negrita">/</span> Servicio de Neurología, Hospital Universitario de Bellvitge</p>
									<br>
									<p>Cancer immunotherapy has resulted in a paradigm shift in onco-hemathology. Immunotherapy may be active, inducing an immunotherapy response in vivo. This is the case of vaccine or oncolytic virus that directly sensitizes the
										immune system to tumor-specific antigens. Or it may be passive, by transferring cells or antibodies which have been previously manipulated in vitro, and that will target the tumor or will modulate the natural immune response of
										the patient. Among immunomodulatory strategies, immune check point inhibitors (ICPi) are antagonistic antibodies that block specific immune checkpoint molecules, aiming to enhance general immunoreactivity by augmenting
										co-stimulatory molecules or blocking inhibitory molecules. Unfortunately, by unbalancing the immune system, these immunotherapies may however generate dysimmune toxicities.</p>
									<br>
									<p>Neurological immune related adverse events (irNRLAE) induced by ICPi are thought to result due to the loss of maintenance of self-tolerance and a pathological abnormal immunologic activation, which can affect such as the
										peripheral as the central nervous system (CNS). Different irNRLAE have been described, including encephalitis, myelopathy, aseptic meningitis, meningoradiculitis, Guillain-Barré-like syndrome, peripheral neuropathy (including
										mononeuropathy, mononeuritis multiplex, and polyneuropathy) as well as myasthenic syndrome, which often vary in severity from mild transient peripheral neuropathies that resolve spontaneously, to persistent conditions that require
										prolonged treatment. Neuromuscular manifestations are the most common, and frequently overlap syndromes with multiple irNRLAEs or other affected organ systems frequently exist. For example, concomitant myasthenia
										gravis-myositis-myocarditis represents a life-threatening continuum of neuromuscular and cardiac toxicity.</p>
									<br>
									<p>This presentation focuses specially on one of the CNS toxicities, immune-related encephalitis (irENC) reported with ICPi, which despite being less frequent (0.1–0.2% of patients treated with ICPi), tend to be challenging and
										serious, sometimes fatal, highlighting the need for its promptly recognition and treatment. Unfortunately, similar to other irNRLAE, only limited information regarding incidence, characteristics, and outcome of associated with
										irENC is available as most information is derived from isolated case reports or rudimentary safety reports collected in the frame of clinical trials. As a result, the relatively short term collective experience available
										information is widely variable regarding diagnosis as well as treatment approaches. A systematic literature search, up to December 2018 was conducted in PubMed database to review the reported clinical picture of irENC. </p>
									<br>
									<p>Clinical presentation includes change in alertness and attention, confusion, altered behavior, headaches, seizures, short-term memory loss, depressed level of consciousness, focal weakness, speech abnormality and hallucinations
										with sudden, transient, or progressive onset, sometimes resembling limbic encephalitis, with variable intensity and frequently associated to fever. Onset of encephalitis can occur early (within a few weeks) or late (7–12 months)
										after ICPi initiation, and even occur after discontinuation of ICPi therapy. Course is usually monophasic despite relapses have been described. Patients under combination of immunotherapy appeared to suffer more severe and
										refractory syndromes and earlier presentation.</p>
									<br>
									<p>Importantly, patients under ICPi therapy can develop a number of neurological symptoms that may or may not be directly related to their therapy, and neurologic consultation is mandatory. The symptoms associated with irNRLAEs can
										range from mild (grade 1-2) to severe (grade 3-4); however, they are often challenging to diagnose like neuromuscular complications that they may present as generalized symptoms, such as fatigue and weakness, that can also be
										caused by the cancer itself. In the case of irENC, differential diagnosis may rule out metastases, metabolic disorders, stroke, infectious encephalitis and neurological adverse effects of previous therapies such as irradiation.
										After CT scan, lumbar puncture should always be performed and typically CSF shows lymphocytic pleocytosis ( < 250/mm3), with elevated protein (usually < 150 mg/dL) and normal glucose. However, normal CSF may not exclude the
											possibility of irENC and it was strictly normal in 5 cases reported in the literature. MRI of brain ± spine with contrast must be done, and may be unremarkable or show T2 hyperintensities. EEG to evaluate for subclinical
											seizures is recommended.</p> <br>
											<p>The optimal management of neurological irAEs including irENC has not yet been established. Treatment is empirically based on the standard of care for the induced disease, mostly based on expert opinions and the knowledge of
												autoimmune diseases, rather than prospective studies. In a patient with suspected irENC, ICPi may be withholding immediately. Consider concurrent antiviral (i.e., acyclovir) and/or bacterial therapy until negative PCR results
												obtained. Prednisolone doses ranging 1 -2 mg/kg or in those severe cases 1 gr x 3 or 5 days, and plasmapheresis, intravenous immunoglobulin (IVIG) or other or immunosuppressive approaches depending on the evolution have been
												reported to be of benefit. The duration of treatment with immune-suppressive agents has not been tested prospectively but is recommended a full steroid dose treatment course of 2–4 weeks followed by a gradual taper to avoid
												recurrence. Characteristically, neurological symptoms and signs remit within 48-72 hour following initiation of steroid therapy, and in despite in the majority of reported cases, the neurological outcome of the patients has
												been favorable, fatal outcome can be possible.</p>
											<br>
											<p> In summary, the time of irNRLAE, and specifically irENC onset is unpredictable, and evolution may be rapid and life-threatening. Although rare, they will likely be encountered with increasing frequency as ICPi therapy
												expands to other cancers. Early recognition, cessation of immunotherapy, prompt investigation and immunosuppression treatment is crucial for timely improvement of functional outcome and requires a multidisciplinary approach.
											</p>
											<br>
											<br>
											<h6>References:</h6>
											<br>
											<p>1<span class="negrita">.</span> Current Neurology and Neuroscience Reports (2018) 18: 3 2. Curr Opin Neurol 2017, 30:000–000 3. JAMA Neurol. 2017;74(10):1216-1222</p>

								</div>
							</div>

							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<img src="images/ICONOdocumento.png" alt="" height="50px">
									<br>
									<br>
									<h4>CARDIOTOXICITY</h4>
									<br>
									<p>Dra. Elena García Romero <span class="negrita">/</span> Servicio de Cardiología, Hospital Universitario de Bellvitge</p>
									<br>
									<p>Cardiac complications secondary to immunotherapy are rare because they represent less than 1%. However, they are associated with the highest mortality, around 40%. They have been described with all currently approved agents,
										although we have scarce data and only from case reports or small case series. According to a review of the pharmaceutical safety databases, cardiac complications had an incidence of 0.1%, although this number is probably
										underestimated due to the absence of systematic monitoring in trials of this type of complications. On the other hand, it is foreseeable that the incidence will increase since the use of immunotherapy is spreading to many types of
										tumors and, therefore, more patients will be susceptible to be treated with them in the future.</p>
									<br>
									<p>What has been clearly seen is that the risk increases considerably when combination therapy is used (anti-CTLA-4 antibodies with anti PD1 or anti PDL1 antibodies). For example, in patients undergoing combination therapy with
										Ipilipumab (antiCTLA4) and Nivolumab (anti PD1), the incidence of complications was 0.27% compared to 0.06% in patients who underwent treatment with Nivolumab alone.
									</p>
									<br>
									<p>These complications usually appear early, with a median onset of 10 weeks after starting treatment, although they may appear from 2 weeks after its initiation and up to 17 weeks after the end of the treatment. Multiple cardiac
										complications have been described including myocarditis, pericarditis, pericardial effusion, arrhythmias, conduction abnormalities, arterial hypertension, cardiomyopathy, ventricular dysfunction, "Tako-Tsubo" syndrome and even
										acute coronary syndrome. It has been shown that both innate and adaptive immunity promote the development of plaques of atheroma, their progression and destabilization. The presentation can be variable, but we have to think about
										them if the patient reports chest pain, dyspnea, peripheral edema or palpitations. Diagnosis can be difficult, on the one hand because sometimes patients refer nonspecific symptoms and on the other hand because these symptoms may
										be due to disease’s progression, to other complications such as pulmonary thromboembolism or other complications derived from immunotherapy, such as pneumonitis. Mortality is high, with death frequently secondary to refractory
										arrhythmia or cardiogenic shock.</p>
									<br>
									<p>Immune myocarditis is one of the most commonly described cardiac complications in the literature because it can be fulminating, progressive and life-threatening. It may result in heart failure or arrhythmia. It can present itself
										associated with myositis, and also with myasthenia gravis in some cases. It is more common with combination therapy, although up to 66% of cases can occur with single therapy. In addition, we must take into account that up to 51%
										of patients may have a normal LVEF, a difference compared with other causes of myocarditis. The mechanism is explained on the one hand possibly due to cross-reactivity against common antigens and on the other hand because there
										are preclinical data that suggest that both CTLA-4 and PD-1 play critical roles regulating immune homeostasis in the myocardium.</p>
									<br>
									<p>Regarding diagnosis, although there is no evidence of what is the best monitoring strategy to follow, it seems reasonable to try to establish a baseline cardiovascular risk through a detailed clinical history (cardiovascular risk
										factors, previous cardiological history, history of myocarditis, previous use of other cardiotoxic drugs...) and perform an ECG and cardiac biomarkers prior to the start of immunotherapy, especially taking into account the
										potential severity of cardiological complications. In high cardiovascular risk patients or in those with an established cardiac disease, a cardiological assessment would be advisable. Some groups recommend cardiac monitoring
										especially in the first weeks of treatment, with a new ECG and new biomarkers. Once treatment is started, if a cardiac complication is suspected, a new ECG, biomarkers and chest x-ray should be performed to rule out other
										etiologies that may justify the patient's symptoms, both cardiological, like acute coronary syndrome (using cardiac stress testing, heart catheterization or cardiac MRI) or other possible causes (thromboembolism, pneumonitis,
										disease’s progression). It would be advisable to perform continuous cardiac monitoring and refer to a cardiologist to complete the study using echocardiography, cardiac MRI (especially if we suspect myocarditis, since it would be
										the preferred non-invasive technique for diagnosis) and endomyocardial biopsy for patients who are unstable or fail to respond to initial therapy or in whom the diagnosis is in doubt.
									</p>
									<br>
									<p>Holding checkpoint inhibitor therapy is recommended for all grades of cardiac complications, including grade 1 (asymptomatic biomarker elevations), and reinitiating therapy is almost never recommended. Treatment for mild-moderate
										complications (grades 2-3) consists of systemic corticosteroids at doses of 1 or even 2 mg / kg per day. In patients with no response after 3-5 days or in patients with severe toxicity (including moderate to severe decompensation,
										highly abnormal testing, fulminant disease, cardiogenic shock, acute heart failure or with life-threatening arrhythmia), higher doses of corticosteroids are needed and an additional immunosuppressive therapy should be added, such
										as tacrolimus, mycophenolate mofetil or thymoglobulin. It is not recommended to add infliximab as it has been associated with heart failure and its use is contraindicated in doses higher than 5 mg / kg in patients with advanced
										heart failure (Class III / IV). In cases in which myocarditis is suspected, some groups recommend systemic corticosteroids at doses of 1 g per day for 3 days followed by 1 mg / kg / day, evaluating adding other immunosuppressants
										agents if there is no adequate response. Contraction and conduction disturbances may improve after holding immunotherapy and with appropriate treatment. The patient’s disease status must be taken into account before excessive
										support measures are performed. There are no recommendations on the resumption of immunotherapy, although it seems reasonable not to restart it, especially in patients who have presented with immune myocarditis.
									</p>
									<br>
									<br>
									<h6>References:</h6>
									<br>
									<p>1<span class="negrita">.</span> Haanenm J. B. A. G., Carbonell J., Robert C., Kerr K.M., Peters S., Larkin J., et Jordan K. (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis,
										treatment and follow-up. Annals of Oncology 28 (Supplement 4): i119–i142, 2017 doi:10.1093/annonc/mdx225. </p>
									<p>2<span class="negrita">.</span> Wang D., Salem J., Cohen J., Chandra S., Menzer C., Ye F., ...Johnson D. B. (2018). Fatal toxic effects associated with immune checkpoint inhibitors. A systematic review and meta-analysis. JAMA
										Oncol. doi: 10.1001/jamaoncol.2018.3923</p>
									<p>3<span class="negrita">.</span> Brahmer J., Lacchetti C., , Schneider B.J., Atkins M.B., Brassil K.J., Caterino J.M.,... Thompson J. A. (2018). Management of Immune-Related Adverse Events in Patients Treated With Immune
										Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714-1768.</p>
									<p>4<span class="negrita">.</span> Wang D., Okoye G.D., Neilan T. G., Johnson D.B., Moslehi J.J. (2017). Cardiovascular Toxicities Associated with Cancer Immunotherapies. Curr Cardiol Rep 19:21 DOI 10.1007/s11886-017-0835-0</p>
									<p>5<span class="negrita">.</span> Tomita Y., Sueta D., Kakiuchi Y., Saeki S., Saruwatari K., Sakata S., ... Fujii K. (2017). Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a
										complete response to anti-PD-1 immune checkpoint antibody. Annals of Oncology. 28 (11): 2893-2895. doi:10.1093/annonc/mdx326</p>
									<p>6<span class="negrita">.</span> Mahmood S.S., Fradley M. G., et Neilan T. G.(2018). Myocarditis in patients treated with immune checkpoint inhibitors. J AM Coll Cardiol. 71 (16): 1755-1764</p>
								</div>
							</div>

							<div class="contorno wow fadeIn" data-wow-duration="1s">
								<div class="single_right_text text-center">
									<img src="images/ICONOdocumento.png" alt="" height="50px">
									<br>
									<br>
									<h4>TOXICIDAD OSTEOMUSCULAR</h4>
									<br>
									<p>Dr. Francisco Javier Narváez <span class="negrita">/</span> Servicio de Reumatología, Hospital Universitario de Bellvitge</p>
									<br>
									<p>La frecuencia de trastornos autoinmunes reumatológicos inducidos por la inmunoterapia (IRAES: rheumatic immune-related adverse events) se estima en un 5%-6.6%. Aparentemente son más frecuentes con las terapias anti-CTL4A que con
										las anti-PD1. El riesgo es aún más alto en tratamientos combinados o secuenciales CTLA-4/PD-1 en comparación con la monoterapia.</p>
									<br>
									<p>En la mayoría de los casos suelen aparecer en las primeras 12 semanas tras el inicio del tratamiento (70% de los casos en las primeras 8 semanas). Un 40-50% de los pacientes con IRAES presentan también otros efectos adversos no
										reumatológicos de la inmunoterapia. Como sucede con otras complicaciones inmunomediadas, se especula que la aparición de IRAES se asociaría a una mejor respuesta antitumoral.</p>
									<br>
									<p>Los IRAES más frecuentes descritos son la artritis, cuadros similares a la polimialgia reumática, el síndrome seco y diferentes tipos de miopatías. Excepto para el manejo de las miopatías, en el resto de complicaciones reumáticas
										se mantendrá siempre que sea posible la inmunoterapia si está siendo eficaz.</p>
									<br>
									<p>Dejando al lado a las artralgias (cuya frecuencia en los ensayos clínicos oscila entre un 5% y un 16%), la artritis es la complicación reumatológica más frecuente de la inmunoterapia. En más de la mitad de los casos, suelen ser
										cuadros de artritis indiferenciada en forma de oligo o poliartritis, muchas veces asimétrica, no deformante ni erosiva, y transitoria. En otras ocasiones, la artritis se cronifica y adopta el patrón de una enfermedad autoinmune
										sistémica bien definida, siendo los más frecuentes la artritis reumatoide (40%) y las espondiloartropatías, principalmente la artropatía psoriásica y cuadros de artritis reactiva like con afectación ocular y uretritis. En estos
										casos, existen algunas diferencias con las forma clásicas de estas enfermedades. Así, la artritis reumatoide descrita en relación con la inmunoterapia se presenta por igual en ambos sexos, suele ser seronegativa (positividad del
										factor reumatoide: 12%; positividad de los anticuerpos anti-péptido cíclico citrulinado: 27%), cursa desde el inicio de la enfermedad con un importante compromiso de los tendones flexores y extensores de las manos, y generalmente
										es erosiva (con aparición precoz de erosiones). Los cuadros de espondiloartropatía no se asocian con el HLA B27, causan también erosiones precoces y, en el caso de la artropatía psoriásica, no es infrecuente que la clínica
										articular preceda a la aparición de la psoriasis.
									</p>
									<br>
									<p>El tratamiento de inicio de la artritis en los pacientes con inmunoterapia son los antiinflamatorios no esteroideos (AINE) y los glucocorticoides (prednisona o metilprednisonolna) a dosis medias o bajas. En caso de persistencia o
										ineficacia, se añadirá hidroxicloroquina o metotrexato. En pacientes refractarios, se han ensayado tratamientos biológicos de rescate (principalmente los antagonistas del TNF alfa, sobretodo infliximab, y tocilizumab), sin que la
										evidencia preliminar existente hasta la fecha demuestre un aumento del riesgo de efectos adversos infecciosos, ni pérdida de eficacia en la respuesta antitumoral en estos pacientes.</p>
									<br>
									<p>Los cuadros de polimialgia reumática like se han descrito sobretodo en relación con las terapias anti-PD1. A diferencia de las polimialgia reumática clásica, los reactantes de fase aguda no siempre están elevados y la artritis
										tiene un gran protagonismo en la clínica rizomélica. Suelen responder bien a los glucocorticoides, aunque a veces se necesiten dosis medias o altas para conseguir la remisión clínica. En casos corticodependientes (pacientes que
										recaen con dosis bajas de prednisona), parece ser eficaz el metotrexato. Aunque raro, se han descrito algunos casos de polimialgia reumática asociada a arteritis de células gigantes confirmada mediante biopsia de arteria temporal,
										por lo que ésta posibilidad se debe tener en cuenta en la evaluación de estos pacientes.</p>
									<br>
									<p>El síndrome seco que aparece como complicación de la inmunoterapia suele instaurarse de forma aguda y tener un curso rápidamente progresivo. La sequedad oral es tanto o más manifiesta que la sequedad ocular, que puede estar
										ausente. A diferencia del síndrome de Sjögren, la inmunología específica (anticuerpos anti-Ro) es negativa y la aparición de parotidomegalia es muy rara. Suele responder de forma parcial o completa a los glucocorticoides a dosis
										medias/bajas y a los sialogogos (pilocarpina).</p>
									<br>
									<p>Se han descrito diferentes tipos de miositis como complicación de la inmunoterapia. La más frecuente es la polimiositis. También se han documentado algunos casos de dermatomiositis, miofascitis (inflamación simultánea de las
										fascias musculares y de la musculatura proximal y distal de las extremidades inferiores) y de miopatía necrotizante. En términos generales, la elevación de la enzimas musculares en estos pacientes suele ser muy acusada (CPK x
										10-100 IU/l). Además de la afectación de la musculatura proximal, hay casos descritos con compromiso respiratorio, alguno de ellos mortales, y con afectación de los músculos oculares. También es frecuente (32%) la presencia
										concomitante de miocarditis en estos enfermos. Para su diagnóstico son útiles las pruebas de imagen y la biopsia muscular, que suele mostrar los hallazgos típicos. Para el manejo de esta complicación, además de glucocorticoides a
										dosis altas e inmunosupresores, suele ser necesaria la suspensión temporal de la inmunoterapia. Estos pacientes responden menos a las inmunoglobulinas endovenosas.
									</p>
									<br>
									<p>Por último, se han descrito diferentes enfermedades autoinmunes aparentemente inducidas por la inmunoterapia, principalmente sarcoidosis (con afección pulmonar, cutánea, muscular y del sistema nervioso central), así como también
										casos de esclerosis sistémica, fascitis eosinofílica, nefritis lúpica, vasculitis distintas de la arteritis de células gigantes (granulomatosis con poliangitis y vasculitis de órgano único afectando sistema nervioso central,
										retina, o útero), enfermedad de Vogt-Koyanagi-Harada like, síndrome RS3PE y síndrome vascular acral paraneoplásico. Así mismo se ha documentado la exacerbación con la inmunoterapia de una enfermedad autoinmune pre-existente,
										siendo especialmente frecuente en la psoriasis, aunque también se ha descrito en pacientes con artritis reumatoide, polimialgia reumática, síndrome de Sjögren primario, y púrpura trombocitopénica autoinmune. En la mayoría de los
										casos, el brote de actividad suele ser de leve a moderada intensidad y generalmente transitorio. Ésto debe tenerse en cuenta a la hora de valorar el riesgo/beneficio de la indicación en pacientes con una enfermedad autoinmune de
										base, pero no es a priori una contraindicación absoluta para la inmunoterapia.
									</p>
									<br>
									<br>
									<h6>Bibliografía:</h6>
									<br>
									<p>1<span class="negrita">.</span> Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis
										with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 2018;17:1040-5</p>
									<p>2<span class="negrita">.</span> Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet
										ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective
										cohort study. Ann Rheum Dis 2018;77:393-8</p>
									<p>3<span class="negrita">.</span> Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018;378:158-68</p>
									<p>4<span class="negrita">.</span> Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 2018;14:569-79</p>
									<p>5<span class="negrita">.</span> Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis BMC Med 2015;13:211</p>
									<p>6<span class="negrita">.</span> Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One 2016;11(7):e0160221</p>
									<p>7<span class="negrita">.</span> Gambichler T, Strutzmann S, Tannapfel A, Susok L. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade. BMC Cancer 2017;17:327</p>
									<p>8<span class="negrita">.</span> Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling
										L. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:12-23</p>

								</div>
							</div>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>





	<section>
		<div class="container">
			<div class="row">
				<div class="parrafo text-center wow fadeIn" data-wow-duration="1.5s">
					<h3>ÍNDICE</h3>
				</div>

				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video01.html">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_left_icon">
								<img src="images/LOGOsoloBLANCO.png" alt="">
							</div>

							<div class="single_right_text">
								<h4>1<span class="negrita">.</span> La revolución de la inmunoterapia en cáncer</h4>
								<div class="separator2"></div>
								<p class="izquierda">Dr. Ernest Nadal</p>
							</div>
						</div>
					</a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video02.html">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_left_icon">
								<img src="images/LOGOsoloBLANCO.png" alt="">
							</div>

							<div class="single_right_text">
								<h4>2<span class="negrita">.</span> Manejo de la toxicidad inducida por inmunoterapia</h4>
								<div class="separator2"></div>
								<p class="izquierda">Dr. Juan Martín-Liberal</p>
							</div>
						</div>
					</a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video03.html">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_left_icon">
								<img src="images/LOGOsoloBLANCO.png" alt="">
							</div>

							<div class="single_right_text">
								<h4>3<span class="negrita">.</span> Manejo del paciente</h4>
								<div class="separator2"></div>
								<p class="izquierda">Dra. Eva Coma<br>Dra. Xesca Mitjavila<br>Dra. Irene Cabello<br>Dr. Gabriel Moreno</p>
							</div>
						</div>
					</a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video04.html">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_left_icon">
								<img src="images/LOGOsoloBLANCO.png" alt="">
							</div>

							<div class="single_right_text">
								<h4>4<span class="negrita">.</span> Toxicidad cutánea, endocrinológica y pulmonar</h4>
								<div class="separator2"></div>
								<p class="izquierda">Dr. Ernest Nadal<br>Dra. Samanta Aso<br>Dra. Inma Peiró<br>Dra. Anna Jucglà</p>
							</div>
						</div>
					</a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video05.html">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_left_icon">
								<img src="images/LOGOsoloBLANCO.png" alt="">
							</div>

							<div class="single_right_text">
								<h4>5<span class="negrita">.</span> Toxicidad digestiva y renal</h4>
								<div class="separator2"></div>
								<p class="izquierda">Dr. Juan Martín-Liberal<br>Dra. Silvia Salord<br>Dra. Juliana Bordignon</p>
							</div>
						</div>
					</a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video06.html">
						<div class="contornoActivo wow fadeIn" data-wow-duration="1s">
							<div class="single_left_icon">
								<img src="images/LOGOsoloBLANCO.png" alt="">
							</div>

							<div class="single_right_text">
								<h4>6<span class="negrita">.</span> Toxicidad neurológica</h4>
								<div class="separator2"></div>
								<p class="izquierda">Dra. Eva Doming<br>Dra. Roser Velasco<br>Dra. Elena García<br>Dr. Francisco J. Narváez</p>
							</div>
						</div>
					</a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">
					<a href="video07.html">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_left_icon">
								<img src="images/LOGOsoloBLANCO.png" alt="">
							</div>

							<div class="single_right_text">
								<h4>7<span class="negrita">.</span> Conclusiones</h4>
								<div class="separator2"></div>
								<p class="izquierda">Dr. Ernest Nadal<br>Dr. Juan Martín-Liberal</p>
							</div>
						</div>
					</a>
				</div>
				<div class="col-md-6 col-sm-6 col-xs-12">

				</div>
			</div>
		</div>
	</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>





	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>

</html>
